Feverfew

Commonly used for

MigraineInflammation

What is it? / Overview

Feverfew's parthenolide content is thought to inhibit serotonin release from platelets and reduce inflammatory prostaglandin production, both implicated in migraine pathophysiology. Effect is preventive and cumulative, not acute.

How is it used? / Administration

Form: Standardized leaf extract (0.2–0.4% parthenolide) or freeze-dried leaf capsules

Typical dose studied: 100–300 mg/day standardized extract, or 50–114 mg/day freeze-dried leaf

Timing: Daily, consistently -- preventive effect builds over 4-8 weeks; not for treating an active migraine

Evidence is mixed across trials, partly from inconsistent parthenolide standardization between products -- look for a label stating parthenolide content.

How well does it work? / Evidence

~ Moderate evidence

Who should avoid it?

Avoid with: Bleeding disorder / Coagulopathy

Interacts with: Anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel) -- theoretical additive bleeding risk

Already taking it? Do not stop abruptly after long-term use -- can cause 'post-feverfew syndrome' (rebound headache, anxiety, muscle stiffness); taper instead. Avoid during pregnancy (traditional uterine-stimulant use) and while breastfeeding.

Research & references

Pittler MH, Ernst E. (2004). Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. Diener HC et al. (2005). Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract in migraine prevention. Cephalalgia.